The influence of subclinical active inflammation on IFX pharmacokinetic modeling and disease progression assessment: findings from a prospective real-world study in inflammatory bowel disease patients.
Magro F, Fernandes S, Patita M, Arroja B, Lago P, Rosa I, de Sousa HT, Ministro P, Mocanu I, Vieira A, Castela J, Moleiro J, Roseira J, Cancela E, Sousa P, Portela F, Correia L, Moreira P, Dias S, Afonso J, Danese S, Peyrin-Biroulet L, Vucicevic KM, Santiago M.
Magro F, et al. Among authors: vucicevic km.
J Crohns Colitis. 2024 Jan 19:jjae014. doi: 10.1093/ecco-jcc/jjae014. Online ahead of print.
J Crohns Colitis. 2024.
PMID: 38243908